CLINICAL EVALUATION OF CARPHENAZINE AND PIPERACETAZINE IN PREVIOUSLY PLACEBO-TREATED CHRONIC SCHIZOPHRENICS
BESSIE CLAFFEY M.D.1,
LESTER H. MARGOLIS M.D.2, , and
WILLIAM MANDEL M.D.3
1 Staff Psychiatrist, Nape State Hospital, Imola, Calif.
2 Consultant, Nape State Hospital, Imola, Calif.
3 Chief of Research, Nape State Hospital, Imola, Calif.
Carphenazine and piperacetazine, two new phenothiazines, were given to 80 chronic schizophrenic patients for 4 to 9 months. These patients had previously served as control subjects in a controlled drug evaluation and had not improved.
A global rating of moderate or marked improvement over their pre-study status was observed in 73% of the patients. There were no statistically significant differences between the drugs in degree of improvement or incidence of extrapyramidal reactions. Both drugs were considered effective phenothiazines for the chronic schizophrenic patient.
